Revolution Medicines, Inc. - Equity Warrant - Penyata Pendapatan (TTM)

Revolution Medicines, Inc. - Equity Warrant
SIMBOL INI TIDAK AKTIF LAGI

Penyata Pendapatan (TTM)

Revolution Medicines, Inc. - Equity Warrant Penyata Pendapatan menunjukkan perubahan dalam pendapatan dan perbelanjaan sepanjang tempoh masa tertentu. Data Penyata Pendapatan termasuk Jualan dan Hasil, Untung Kasar, Penyelidikan dan Pembangunan (R&D), Jualan, Perbelanjaan Am dan Pentadbiran (SG&A), Pendapatan Operasi, Perbelanjaan Cukai Pendapatan, Perbelanjaan Faedah, Pendapatan Bukan Operasi, Perolehan sesaham (EPS), dan Saham Diterbitkan.

Semua nombor adalah kali 1,000,000 kecuali setiap unit saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
Hasil 46 43 42 40 29 29 27 27 30 35 35 30 26 12 5 1 1
Perubahan (%) -7.20 -3.29 -3.19 -28.73 2.47 -8.69 1.56 8.27 19.89 -1.59 -15.20 -11.37 -55.75 -60.57 -83.75 0.00
% daripada Hasil 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Kos jualan 123 132 146 159 170 187 203 218 241 253 266 149 341 411 460 421 541
Perubahan (%) 7.75 10.13 8.94 7.31 9.79 8.36 7.44 10.56 5.17 4.92 -43.91 128.83 20.67 11.93 -8.56 28.46
% daripada Hasil 264.97 307.68 350.40 394.30 593.68 636.09 754.85 798.55 815.41 715.30 762.67 504.42 1,302.32 3,551.33 10,081.43 56,728.03 72,871.97
Keuntungan Operasi Kasar -76 -89 -104 -118 -142 -158 -176 -190 -211 -218 -231 -119 -315 -400 -456 -420 -540
Perubahan (%) 16.82 16.60 13.78 19.56 11.28 11.54 8.33 10.89 3.11 5.98 -48.25 163.50 27.03 14.03 -7.81 28.51
% daripada Hasil -164.97 -207.68 -250.40 -294.30 -493.68 -536.09 -654.85 -698.55 -715.41 -615.30 -662.67 -404.42 -1,202.32 -3,451.33 -9,981.43 -56,628.03 -72,771.97
SG&A 20 21 23 25 28 30 33 36 38 41 45 49 54 62 72 79 88
Perubahan (%) 8.41 7.00 9.62 9.75 10.39 7.77 8.86 7.40 5.78 10.32 9.91 10.32 14.25 15.50 9.87 11.46
% daripada Hasil 42.67 49.85 55.16 62.46 96.17 103.61 122.28 131.08 130.02 114.71 128.60 166.67 207.46 535.59 1,568.88 10,607.28 11,823.32
R&D 154 76
Perubahan (%)
% daripada Hasil 520.21 10,289.35
OpEx 143 154 169 184 198 217 235 253 279 294 310 352 395 473 532 576 628
Perubahan (%) 7.84 9.70 9.03 7.65 9.88 8.28 7.64 10.11 5.26 5.67 13.35 12.33 19.79 12.40 8.28 9.11
% daripada Hasil 307.64 357.54 405.55 456.76 689.85 739.70 877.14 929.63 945.43 830.01 891.27 1,191.30 1,509.77 4,086.92 11,650.31 77,624.66 84,695.28
Pendapatan operasi -96 -111 -127 -144 -169 -188 -209 -226 -249 -258 -275 -322 -369 -462 -527 -575 -628
Perubahan (%) 15.09 14.74 13.03 17.84 11.13 10.93 8.42 10.34 3.52 6.66 16.95 14.50 25.15 14.23 9.07 9.12
% daripada Hasil -207.64 -257.54 -305.55 -356.76 -589.85 -639.70 -777.14 -829.63 -845.43 -730.01 -791.27 -1,091.30 -1,409.77 -3,986.92 -11,550.31 -77,524.66 -84,595.28
Perbelanjaan Faedah -0 -0 -0 -0 -0 -0 0 0 0 -0 -0 -0 -0
Perubahan (%) -11.25 -12.68 -30.65 -39.53 -53.85 -100.00 NaN NaN -0.00 -0.00 -0.00
% daripada Hasil -0.17 -0.17 -0.15 -0.11 -0.09 -0.04 0.00 0.00 0.00 -2.62 -6.64 -40.84 -40.84
Pendapatan bersih -89 -108 -126 -143 -169 -187 -208 -224 -245 -249 -259 -296 -331 -436 -484 -519 -567
Perubahan (%) 22.14 16.33 13.58 18.00 10.95 10.94 8.15 9.08 1.56 4.20 14.31 11.85 31.70 10.98 7.21 9.22
% daripada Hasil -191.17 -251.63 -302.68 -355.11 -587.91 -636.58 -773.42 -823.65 -829.80 -702.95 -744.36 -1,003.36 -1,266.19 -3,768.28 -10,606.04 -69,973.99 -76,423.32

Source: Capital IQ

Other Listings
US:RVMDW USD0.20
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista